Clinical Trial - Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy - Pancreatic Cancer

A patient’s personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines to help doctors use this information to make a decision. The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. The patient’s personal and familial history of cancer will be reviewed and researchers will offer genetic testing.

Study Type : Observational
Estimated Enrollment : 375 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
Actual Study Start Date : February 24, 2017
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2022

Contacts:

Contact: Matthew B Yurgelun, MD 617-632-6835 matthew_yurgelun@dfci.harvard.edu
Contact: Chinedu Ukaegbu 617-632-6355 chinedu_ukaegbu@dfci.harvard.edu

Location:

United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Matthew B Yurgelun, MD    617-632-6835
Principal Investigator: Matthew B Yurgelun, MD
ClinicalTrials.gov Identifier: NCT03060720
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.